Compare KRRO & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | ONCY |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 94.0M |
| IPO Year | 2019 | 2002 |
| Metric | KRRO | ONCY |
|---|---|---|
| Price | $13.68 | $1.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $34.80 | $7.33 |
| AVG Volume (30 Days) | 197.4K | ★ 841.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,392,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $0.33 |
| 52 Week High | $55.89 | $1.51 |
| Indicator | KRRO | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 58.66 |
| Support Level | $12.17 | $0.94 |
| Resistance Level | $15.11 | $1.13 |
| Average True Range (ATR) | 1.07 | 0.09 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 67.20 | 90.63 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.